ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2008
Differential expression of decorin by human malignant and benign vascular tumors.
Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Immunostaining for VEGF and Decorin Predicts Poor Survival and Recurrence in Canine Soft Tissue Sarcoma.Veterinary sciences · 2023Article
- The Role of Decorin and Biglycan Signaling in Tumorigenesis.Frontiers in oncology · 2021Review
- Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.Scientific reports · 2020Article
- Expression based biomarkers and models to classify early and late-stage samples of Papillary Thyroid Carcinoma.PloS one · 2020Article
- Metabolic Disorder of Extracellular Matrix Mediated by Decorin Upregulation Is Associated With Brain Arteriovenous Malformation Diffuseness.Frontiers in aging neuroscience · 2020Article
- Protective Role of Decorin in Primary Hepatocellular Carcinoma.Frontiers in oncology · 2020Article
- Decorin Expression in Human Vulva Carcinoma: Oncosuppressive Effect of Decorin cDNA Transduction on Carcinoma Cells.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2019Article
- Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors.Oncology letters · 2019Article
- Small Leucine-Rich Proteoglycans in Skin Wound Healing.Frontiers in pharmacology · 2019Review
- Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment.Oncotarget · 2018Review
- Human Metaplastic Breast Carcinoma and Decorin.Cancer microenvironment : official journal of the International Cancer Microenvironment Society · 2017Article
- Epigenetic Silencing of the Key Antioxidant Enzyme Catalase in Karyotypically Abnormal Human Pluripotent Stem Cells.Scientific reports · 2016Article
- Decorin as a multivalent therapeutic agent against cancer.Advanced drug delivery reviews · 2016Review
- Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.New horizons in translational medicine · 2016Article
- Antiangiogenic mechanisms and factors in breast cancer treatment.Journal of carcinogenesis · 2016Review
- Decorin in Human Colon Cancer: Localization In Vivo and Effect on Cancer Cell Behavior In Vitro.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2015Article
- Rare Case of Spindle Cell Haemangioma.Journal of clinical and diagnostic research : JCDR · 2015Article
- Pivotal role for decorin in angiogenesis.Matrix biology : journal of the International Society for Matrix Biology · 2015Review
- Decorin: A Growth Factor Antagonist for Tumor Growth Inhibition.BioMed research international · 2015Review
- Decreased decorin expression in the tumor microenvironment.Cancer medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An increasing amount of evidence indicates that a small extracellular chondroitin/dermatan sulfate proteoglycan, decorin, is indirectly involved in angiogenesis. Given that angiogenesis is a sine qua non for tumor growth and progression, we attempted to examine whether human malignant vascular tumors differ from human benign vascular tumors in terms of their decorin expression and synthesis. CD31 immunostaining demonstrated that the human malignant vascular tumors Kaposi's sarcoma and angiosarcoma were filled with capillary-like structures, whereas in benign cavernous and capillary hemangiomas, blood vessels were not as abundantly present. By utilizing in situ hybridization and immunocytochemical assays for decorin, we showed that there was no detectable decorin mRNA expression or immunoreactivity within the tumor mass in the Kaposi's sarcoma or angiosarcoma group. Instead, decorin was expressed in the connective tissue stroma lining the sarcoma tissue. In contrast to sarcomas, in hemangiomas, decorin mRNA expression and immunoreactivity were observed also within the tumor mass, particularly in the connective tissue stroma surrounding the clusters of intratumoral blood vessels. Finally, distribution of type I collagen was found to be similar to that of decorin in these tumor tissues. Our findings can be explained with different states of angiogenesis in dissimilar growths. In sarcomas, angiogenesis is extremely powerful, whereas in hemangiomas, angiogenesis has ceased. Thus, decorin is likely to possess a suppressive effect on human tumor angiogenesis in vivo, as previously described by studies using different experimental models. Decorin certainly provides a usable biomarker for distinguishing between benign and malignant vascular tumors in patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.